SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
BURLINGTON, Mass., Oct. 16, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2017 financial results on Thursday, October 26, 2017, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 99745674. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc.
Steven Chehames
Investor Relations
+1-781-425-1659
[email protected]
http://www.lemaitre.com
